Male carriers of BRCA mutations are at higher risk of developing prostate cancer. Many issues are still unanswered and are currently being studied, including differences between BRCA1 and BRCA2, screening and specific protocols, the role of active surveillance, and the choice of definitive treatment.
European urology focus. 2019 May 27 [Epub ahead of print]
Daniel Halstuch, Yaara Ber, David Margel
Department of Urology, Rabin Medical Center, Petah Tikva, Israel., Department of Urology, Rabin Medical Center, Petah Tikva, Israel; Division of Surgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: .